“Triple Threat-Triple Benefit: The Rise of GLP1-GCG-FGF21 Tritagonists in Tomorrow’s Metabolic Medicine ”. Diabzen, vol. 3, no. 3, Dec. 2025, pp. 43-48, https://www.thediabzen.com/index.php/d/article/view/19.